The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Human Serum Paraoxonase/Arylesterase’s Retained Hydrophobic N-Terminal Leader Sequence Associates With HDLs by Binding Phospholipids: Apolipoprotein A-I Stabilizes Activity
Abstract
Abstract—In serum, human paraoxonase/arylesterase (PON1) is found exclusively associated with high density lipoprotein (HDL) and contributes to its antiatherogenic properties by inhibiting low density lipoprotein (LDL) oxidation. Difficulties in purifying PON1 from apolipoprotein A-I (apoA-I) suggested that PON1’s association with HDL may occur through a direct binding between these 2 proteins. An unusual property of PON1 is that the mature protein retains its hydrophobic N-terminal signal sequence. By expressing in vitro a mutant PON1 with a cleavable N-terminus, we demonstrate that PON1 associates with lipoproteins through its N-terminus by binding phospholipids directly rather than binding apoA-I. Nonetheless, apoA-I stabilized arylesterase activity more than did phospholipid alone, apoA-II, or apoE. Consequently, we studied the role of apoA-I in PON1 expression and HDL association in mice genetically deficient in apoA-I. Though present in HDL fractions at decreased levels, PON1 arylesterase activity was less stable than in control mice. Furthermore, PON1 could be competitively removed from HDL by phospholipids, suggesting that PON1’s retained N-terminal peptide allows transfer of the enzyme between phospholipid surfaces. Thus, our data suggest that PON1 is stabilized by apoA-I, and its binding to HDL and physiological distribution are dependent on the direct binding of the retained hydrophobic N-terminus to phospholipids optimally presented in association with apoA-I.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
A new method for predicting signal sequence cleavage sites
von Heijne, G. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.11.4683 · Cited by 4,508
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Aviram, M., Rosenblat, M., Bisgaier, C. L., Newton, R. S., Primo-Parmo, S. L., & La Du, B. N. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1649 · Cited by 1,168
Self-citationWatson, A. D., Berliner, J. A., Hama, S. Y., La Du, B. N., Faull, K. F., Fogelman, A. M., & Navab, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118359 · Cited by 1,154
Self-citationMice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
Shih, D. M., Gu, L., Xia, Y.-R., Navab, M., Li, W.-F., Hama, S., Castellani, L. W., Furlong, C. E., Costa, L. G., Fogelman, A. M., et al. (1998) · Nature · doi:10.1038/28406 · Cited by 1,078
Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein
Mackness, M. I., Arrol, S., & Durrington, P. N. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80962-3 · Cited by 977
Van Lenten, B. J., Hama, S. Y., de Beer, F. C., Stafforini, D. M., McIntyre, T. M., Prescott, S. M., La Du, B. N., Fogelman, A. M., & Navab, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118345 · Cited by 840
Self-citationMACKNESS, M., ARROL, S., ABBOTT, C., & DURRINGTON, P. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90183-u · Cited by 816
Gan, K. N., Smolen, A., Eckerson, H. W., & La Du, B. N. (1991) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07065-5 · Cited by 596
Self-citation
Cited by
Draganov, D. I., Teiber, J. F., Speelman, A., Osawa, Y., Sunahara, R., & La Du, B. N. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400511-jlr200 · Cited by 715
Self-citationHarel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir, H., Ravelli, R. B. G., McCarthy, A., Toker, L., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb767 · Cited by 646
Aviram, M., & Rosenblat, M. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.06.030 · Cited by 434
Self-citationHuman Serum Paraoxonase (pon1) Isozymes Q and R Hydrolyze Lactones and Cyclic Carbonate Esters
Billecke, S., Draganov, D., Counsell, R., Stetson, P., Watson, C., Hsu, C., & Du, B. N. L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15082-9 · Cited by 402
Self-citationDraganov, D. I., Stetson, P. L., Watson, C. E., Billecke, S. S., & La Du, B. N. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004543200 · Cited by 338
Self-citation
Metadata
- Authors
- Sorenson, R. C., Bisgaier, C. L., Aviram, M., Hsu, C., Billecke, S., & La Du, B. N.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1999-09
- Volume
- 19
- Issue
- 9
- Pages
- 2214-2225
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2054847996
- Cited by
- 324
- References
- 42
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Serum Paraoxonase/Arylesterase’s Retained Hydrophobic N-Terminal Leader Sequence Associates With HDLs by Binding Phospholipids: Apolipoprotein A-I Stabilizes Activity. https://app.cochat.ai/papers/10.1161/01.atv.19.9.2214
- The paper
- Sorenson, R. C., Bisgaier, C. L., Aviram, M., Hsu, C., Billecke, S., & La Du, B. N. (1999). Human Serum Paraoxonase/Arylesterase’s Retained Hydrophobic N-Terminal Leader Sequence Associates With HDLs by Binding Phospholipids: Apolipoprotein A-I Stabilizes Activity. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.19.9.2214
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.